Etiological Aspects for the Occurrence of Diabetic Neuropathy and the Suggested Measures

Diabetic neuropathy is a painful devitalizing complication of diabetes affecting almost 20% individuals with this disease. Based on the area where neurons are mostly affected, it is categorized into four different types, proximal, peripheral, autonomic, and focal, and each type shows varying symptom...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurophysiology (New York) 2020-03, Vol.52 (2), p.159-168
Hauptverfasser: Grover, M., Makkar, R., Sehgal, A., Seth, S. K., Gupta, J., Behl, T.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 168
container_issue 2
container_start_page 159
container_title Neurophysiology (New York)
container_volume 52
creator Grover, M.
Makkar, R.
Sehgal, A.
Seth, S. K.
Gupta, J.
Behl, T.
description Diabetic neuropathy is a painful devitalizing complication of diabetes affecting almost 20% individuals with this disease. Based on the area where neurons are mostly affected, it is categorized into four different types, proximal, peripheral, autonomic, and focal, and each type shows varying symptoms like numbness, gastric problems, heart problems, etc. Sometimes, these symptoms are mistakenly taken as those of gastric disorders, heart attack, or arrhythmia, with paying no attention to the inflamed neuronal supply in the particular area. Despite being aware of the symptoms, it is still a major challenging task for concerned endocrinologists and neurologists to diagnose it among the participants in clinics or in clinical trials. Treatment of diabetic neuropathy involves three major approaches, maintenance of the sugar level, pathogenetic treatment, and relieve of pain. Certain recommended drugs for pain relief are antidepressants (like duloxetine), GABA analogs (like gabapentin or pregabalin), and some other proposed treatments under research (like α-lipoic acid, aldose reductase inhibitors, or benfoitamine). The current drugs which are being provided for this disease are all indirectly acting and doesn’t have any direct action on the neuronal part. So, currently the need for today is to provide most potent drugs or combination of drugs to relieve the pain of diabetic neuropathy individuals by acting directly on the nerves without laying any side effects.
doi_str_mv 10.1007/s11062-020-09865-2
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2450779271</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A640620813</galeid><sourcerecordid>A640620813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-28de356ffe983083a03e18224b0bd817a3634d36333396259d0e24869fcf0b33</originalsourceid><addsrcrecordid>eNp9kU1rXCEUhiW0kGmaP5CV0FUXd3rU-6HLIU3bwDSBJIvsxPEe7xhmrlP1Qubf12QKYaBEQUGf5_jxEnLBYM4Aum-JMWh5BRwqULJtKn5CZqzpRKXK9gcyA1BQcdV1p-RTSk8A0ErVzMjjVfZhEwZvzYYu0g5tTtSFSPMa6a21U4w4WqTB0e_erDB7S29wimFn8npPzdi_kvfTMGDK2NPfaNIUMX0mH53ZJDz_N5-Rhx9XD5e_quXtz-vLxbKyNYdccdmjaFrnUEkBUhgQyCTn9QpWvWSdEa2o-zKUplreqB6Q17JVzjpYCXFGvhzK7mL4M5Ur6KcwxbGcqHndQNcp3rE3ajAb1H50IUdjtz5ZvWjr8nMg2Uut-X-o0nvcehtGdL6sHwlfj4TCZHzOg5lS0tf3d8csP7A2hpQiOr2LfmviXjPQLxnqQ4a6ZKhfM9S8SOIgpQKPA8a3171j_QXyPpsq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2450779271</pqid></control><display><type>article</type><title>Etiological Aspects for the Occurrence of Diabetic Neuropathy and the Suggested Measures</title><source>SpringerLink Journals - AutoHoldings</source><creator>Grover, M. ; Makkar, R. ; Sehgal, A. ; Seth, S. K. ; Gupta, J. ; Behl, T.</creator><creatorcontrib>Grover, M. ; Makkar, R. ; Sehgal, A. ; Seth, S. K. ; Gupta, J. ; Behl, T.</creatorcontrib><description>Diabetic neuropathy is a painful devitalizing complication of diabetes affecting almost 20% individuals with this disease. Based on the area where neurons are mostly affected, it is categorized into four different types, proximal, peripheral, autonomic, and focal, and each type shows varying symptoms like numbness, gastric problems, heart problems, etc. Sometimes, these symptoms are mistakenly taken as those of gastric disorders, heart attack, or arrhythmia, with paying no attention to the inflamed neuronal supply in the particular area. Despite being aware of the symptoms, it is still a major challenging task for concerned endocrinologists and neurologists to diagnose it among the participants in clinics or in clinical trials. Treatment of diabetic neuropathy involves three major approaches, maintenance of the sugar level, pathogenetic treatment, and relieve of pain. Certain recommended drugs for pain relief are antidepressants (like duloxetine), GABA analogs (like gabapentin or pregabalin), and some other proposed treatments under research (like α-lipoic acid, aldose reductase inhibitors, or benfoitamine). The current drugs which are being provided for this disease are all indirectly acting and doesn’t have any direct action on the neuronal part. So, currently the need for today is to provide most potent drugs or combination of drugs to relieve the pain of diabetic neuropathy individuals by acting directly on the nerves without laying any side effects.</description><identifier>ISSN: 0090-2977</identifier><identifier>EISSN: 1573-9007</identifier><identifier>DOI: 10.1007/s11062-020-09865-2</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aldehyde reductase ; Aldose reductase ; Analgesics ; Antidepressants ; Arrhythmia ; Autonomic nervous system ; Biomedical and Life Sciences ; Biomedicine ; Clinical trials ; Development and progression ; Diabetes ; Diabetes mellitus ; Diabetic neuropathies ; Diabetic neuropathy ; Drugs ; Duloxetine ; Gabapentin ; Gastrointestinal diseases ; Heart attack ; Inflammation ; Lipoic acid ; Myocardial infarction ; Nerves ; Neurosciences ; Pain ; Polyols ; Type 2 diabetes ; γ-Aminobutyric acid</subject><ispartof>Neurophysiology (New York), 2020-03, Vol.52 (2), p.159-168</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-28de356ffe983083a03e18224b0bd817a3634d36333396259d0e24869fcf0b33</citedby><cites>FETCH-LOGICAL-c420t-28de356ffe983083a03e18224b0bd817a3634d36333396259d0e24869fcf0b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11062-020-09865-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11062-020-09865-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Grover, M.</creatorcontrib><creatorcontrib>Makkar, R.</creatorcontrib><creatorcontrib>Sehgal, A.</creatorcontrib><creatorcontrib>Seth, S. K.</creatorcontrib><creatorcontrib>Gupta, J.</creatorcontrib><creatorcontrib>Behl, T.</creatorcontrib><title>Etiological Aspects for the Occurrence of Diabetic Neuropathy and the Suggested Measures</title><title>Neurophysiology (New York)</title><addtitle>Neurophysiology</addtitle><description>Diabetic neuropathy is a painful devitalizing complication of diabetes affecting almost 20% individuals with this disease. Based on the area where neurons are mostly affected, it is categorized into four different types, proximal, peripheral, autonomic, and focal, and each type shows varying symptoms like numbness, gastric problems, heart problems, etc. Sometimes, these symptoms are mistakenly taken as those of gastric disorders, heart attack, or arrhythmia, with paying no attention to the inflamed neuronal supply in the particular area. Despite being aware of the symptoms, it is still a major challenging task for concerned endocrinologists and neurologists to diagnose it among the participants in clinics or in clinical trials. Treatment of diabetic neuropathy involves three major approaches, maintenance of the sugar level, pathogenetic treatment, and relieve of pain. Certain recommended drugs for pain relief are antidepressants (like duloxetine), GABA analogs (like gabapentin or pregabalin), and some other proposed treatments under research (like α-lipoic acid, aldose reductase inhibitors, or benfoitamine). The current drugs which are being provided for this disease are all indirectly acting and doesn’t have any direct action on the neuronal part. So, currently the need for today is to provide most potent drugs or combination of drugs to relieve the pain of diabetic neuropathy individuals by acting directly on the nerves without laying any side effects.</description><subject>Aldehyde reductase</subject><subject>Aldose reductase</subject><subject>Analgesics</subject><subject>Antidepressants</subject><subject>Arrhythmia</subject><subject>Autonomic nervous system</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Clinical trials</subject><subject>Development and progression</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetic neuropathies</subject><subject>Diabetic neuropathy</subject><subject>Drugs</subject><subject>Duloxetine</subject><subject>Gabapentin</subject><subject>Gastrointestinal diseases</subject><subject>Heart attack</subject><subject>Inflammation</subject><subject>Lipoic acid</subject><subject>Myocardial infarction</subject><subject>Nerves</subject><subject>Neurosciences</subject><subject>Pain</subject><subject>Polyols</subject><subject>Type 2 diabetes</subject><subject>γ-Aminobutyric acid</subject><issn>0090-2977</issn><issn>1573-9007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kU1rXCEUhiW0kGmaP5CV0FUXd3rU-6HLIU3bwDSBJIvsxPEe7xhmrlP1Qubf12QKYaBEQUGf5_jxEnLBYM4Aum-JMWh5BRwqULJtKn5CZqzpRKXK9gcyA1BQcdV1p-RTSk8A0ErVzMjjVfZhEwZvzYYu0g5tTtSFSPMa6a21U4w4WqTB0e_erDB7S29wimFn8npPzdi_kvfTMGDK2NPfaNIUMX0mH53ZJDz_N5-Rhx9XD5e_quXtz-vLxbKyNYdccdmjaFrnUEkBUhgQyCTn9QpWvWSdEa2o-zKUplreqB6Q17JVzjpYCXFGvhzK7mL4M5Ur6KcwxbGcqHndQNcp3rE3ajAb1H50IUdjtz5ZvWjr8nMg2Uut-X-o0nvcehtGdL6sHwlfj4TCZHzOg5lS0tf3d8csP7A2hpQiOr2LfmviXjPQLxnqQ4a6ZKhfM9S8SOIgpQKPA8a3171j_QXyPpsq</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Grover, M.</creator><creator>Makkar, R.</creator><creator>Sehgal, A.</creator><creator>Seth, S. K.</creator><creator>Gupta, J.</creator><creator>Behl, T.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20200301</creationdate><title>Etiological Aspects for the Occurrence of Diabetic Neuropathy and the Suggested Measures</title><author>Grover, M. ; Makkar, R. ; Sehgal, A. ; Seth, S. K. ; Gupta, J. ; Behl, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-28de356ffe983083a03e18224b0bd817a3634d36333396259d0e24869fcf0b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aldehyde reductase</topic><topic>Aldose reductase</topic><topic>Analgesics</topic><topic>Antidepressants</topic><topic>Arrhythmia</topic><topic>Autonomic nervous system</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Clinical trials</topic><topic>Development and progression</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetic neuropathies</topic><topic>Diabetic neuropathy</topic><topic>Drugs</topic><topic>Duloxetine</topic><topic>Gabapentin</topic><topic>Gastrointestinal diseases</topic><topic>Heart attack</topic><topic>Inflammation</topic><topic>Lipoic acid</topic><topic>Myocardial infarction</topic><topic>Nerves</topic><topic>Neurosciences</topic><topic>Pain</topic><topic>Polyols</topic><topic>Type 2 diabetes</topic><topic>γ-Aminobutyric acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grover, M.</creatorcontrib><creatorcontrib>Makkar, R.</creatorcontrib><creatorcontrib>Sehgal, A.</creatorcontrib><creatorcontrib>Seth, S. K.</creatorcontrib><creatorcontrib>Gupta, J.</creatorcontrib><creatorcontrib>Behl, T.</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Neurophysiology (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grover, M.</au><au>Makkar, R.</au><au>Sehgal, A.</au><au>Seth, S. K.</au><au>Gupta, J.</au><au>Behl, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Etiological Aspects for the Occurrence of Diabetic Neuropathy and the Suggested Measures</atitle><jtitle>Neurophysiology (New York)</jtitle><stitle>Neurophysiology</stitle><date>2020-03-01</date><risdate>2020</risdate><volume>52</volume><issue>2</issue><spage>159</spage><epage>168</epage><pages>159-168</pages><issn>0090-2977</issn><eissn>1573-9007</eissn><abstract>Diabetic neuropathy is a painful devitalizing complication of diabetes affecting almost 20% individuals with this disease. Based on the area where neurons are mostly affected, it is categorized into four different types, proximal, peripheral, autonomic, and focal, and each type shows varying symptoms like numbness, gastric problems, heart problems, etc. Sometimes, these symptoms are mistakenly taken as those of gastric disorders, heart attack, or arrhythmia, with paying no attention to the inflamed neuronal supply in the particular area. Despite being aware of the symptoms, it is still a major challenging task for concerned endocrinologists and neurologists to diagnose it among the participants in clinics or in clinical trials. Treatment of diabetic neuropathy involves three major approaches, maintenance of the sugar level, pathogenetic treatment, and relieve of pain. Certain recommended drugs for pain relief are antidepressants (like duloxetine), GABA analogs (like gabapentin or pregabalin), and some other proposed treatments under research (like α-lipoic acid, aldose reductase inhibitors, or benfoitamine). The current drugs which are being provided for this disease are all indirectly acting and doesn’t have any direct action on the neuronal part. So, currently the need for today is to provide most potent drugs or combination of drugs to relieve the pain of diabetic neuropathy individuals by acting directly on the nerves without laying any side effects.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s11062-020-09865-2</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-2977
ispartof Neurophysiology (New York), 2020-03, Vol.52 (2), p.159-168
issn 0090-2977
1573-9007
language eng
recordid cdi_proquest_journals_2450779271
source SpringerLink Journals - AutoHoldings
subjects Aldehyde reductase
Aldose reductase
Analgesics
Antidepressants
Arrhythmia
Autonomic nervous system
Biomedical and Life Sciences
Biomedicine
Clinical trials
Development and progression
Diabetes
Diabetes mellitus
Diabetic neuropathies
Diabetic neuropathy
Drugs
Duloxetine
Gabapentin
Gastrointestinal diseases
Heart attack
Inflammation
Lipoic acid
Myocardial infarction
Nerves
Neurosciences
Pain
Polyols
Type 2 diabetes
γ-Aminobutyric acid
title Etiological Aspects for the Occurrence of Diabetic Neuropathy and the Suggested Measures
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T06%3A01%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Etiological%20Aspects%20for%20the%20Occurrence%20of%20Diabetic%20Neuropathy%20and%20the%20Suggested%20Measures&rft.jtitle=Neurophysiology%20(New%20York)&rft.au=Grover,%20M.&rft.date=2020-03-01&rft.volume=52&rft.issue=2&rft.spage=159&rft.epage=168&rft.pages=159-168&rft.issn=0090-2977&rft.eissn=1573-9007&rft_id=info:doi/10.1007/s11062-020-09865-2&rft_dat=%3Cgale_proqu%3EA640620813%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2450779271&rft_id=info:pmid/&rft_galeid=A640620813&rfr_iscdi=true